Eli Lilly and Company (NYSE:LLY) announced on Wednesday, April 1, 2026, that the U.S. Food and Drug Administration (FDA) has approved Foundayo™ (orforglipron) for chronic weight management in adults with obesity, or those who are overweight with at least one weight-related condition.
The approval marks a significant technical milestone in the metabolic health space, as Foundayo is a non-peptide, small-molecule GLP-1 receptor agonist that can be manufactured more easily and taken more flexibly than existing injectable or restricted-oral therapies.
The regulatory clearance was supported by data from the ATTAIN-1 Phase 3 clinical trial.
Results showed that the highest dose of Foundayo produced an average weight loss of 27.3 pounds, or 12.4%, compared to a 2.2-pound (0.9%) loss for the placebo group.
Across the broader trial population, participants lost an average of 25 pounds (11.1%), significantly outperforming the 5.3-pound (2.1%) reduction seen in the control arm.
Lilly confirmed that Foundayo is available by prescription immediately, with initial shipments scheduled to commence on April 6, 2026.
The drug will be distributed through the company’s digital health platform, LillyDirect.
To accelerate market penetration, Lilly introduced a tiered pricing structure: commercial copays will start as low as $25 per month for eligible patients, while self-pay options for those without insurance coverage will begin at $149 per month.
The company also indicated that Medicare Part D access is expected to begin around July 1, 2026.
The safety profile for Foundayo includes warnings common to the GLP-1 class, specifically regarding the potential risk of thyroid C-cell tumors.
Clinical trial data also noted common gastrointestinal side effects, including nausea and vomiting, which typically occurred during the dose-escalation phase.